Phase II Wins, Losses for Obesity Drugs; More Positive Veozah Data; Walking Off T2D

<乌鸦传媒 class="mpt-content-deck">— News and commentary from the endocrinology world

by Kristen Monaco, Senior Staff Writer, 乌鸦传媒 December 4, 2023

Endo Break over a computer rendering of a man with illustrated body organs.

Pemvidutide (2.4 mg), an investigational , helped people with obesity achieve an average 15.6% weight loss after 48 weeks in the phase II MOMENTUM trial, developer Altimmune announced.

Meanwhile, Pfizer said it would not proceed with phase III trials of its for weight loss, after more than half of participants dropped out of a phase II trial due to adverse events; the company is still evaluating a once-daily formulation of the investigational GLP-1 agonist.

While dapagliflozin (Farxiga) and suppressed left ventricular remodeling, it didn't reduce urinary albumin excretion in patients with heart failure and diabetes. (eClinicalMedicine)

Five called on the FDA to include people with obesity in clinical trials prior to a new drug being approved. They also called for drug labels to be updated with more effective dosing for people with obesity.

Novo Nordisk after testing compounded versions of the weight-loss drug semaglutide (Wegovy) and finding them impure. (Reuters)

A nonprofit group of estrogen for gender-affirming care. (STAT)

Oral vitamin D3 supplementation didn't bolster in Mongolian children ages 6 to 13 with vitamin D deficiency, according to a secondary analysis of a randomized trial. (The Lancet Diabetes & Endocrinology)

A was tied to a decreased risk of low handgrip strength in postmenopausal women, a cross-sectional study in Korea showed. (Menopause)

Nonhormonal fezolinetant (Veozah) significantly reduced the frequency and severity of at week 24 versus placebo in the phase IIIb DAYLIGHT study.

Analysis of corporate financial records showed that -- primarily obesity specialists -- $25.8 million over 10 years to promote the company's weight-loss drugs liraglutide (Saxenda) and semaglutide (Wegovy). (Reuters)

The of the osteoporosis treatment teriparatide injection (Forteo), Ambio announced.

Real-world data found that people with obesity taking semaglutide or tirzepatide (Mounjaro) . (Scientific Reports)

Walking more briskly , a meta-analysis suggested. (British Journal of Sports Medicine)

Kristen Monaco is a senior staff writer, focusing on endocrinology, psychiatry, and nephrology news. Based out of the New York City office, she鈥檚 worked at the company since 2015.